AzurRx BioPharma (AZRX) Stock Price, News & Analysis

Company Overview

AzurRx BioPharma, Inc. engages in the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. Its product programs include MS1819, FW-1022: COVID-19 GI infections, and FW-420: Immune Checkpoint Inhibitor Colitis. The company was founded on January 30, 2014 and is headquartered in Delray Beach, FL.

Key Stats

• Today's Range: $0.38 to $0.40
• 50-Day Range: $2.40 to $41.00
• 52-Week Range: $3.36 to $26.30
• Volume: 63,160 shs
• Average Volume: 628,703 shs
• Market Capitalization: $3.68 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AZRX Stock Analysis - Frequently Asked Questions

When did AzurRx BioPharma's stock split?

Shares of AzurRx BioPharma reverse split before market open on Monday, September 13th 2021. The 1-10 reverse split was announced on Monday, September 13th 2021. The number of shares owned by shareholders was adjusted after the closing bell on Monday, September 13th 2021. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did AzurRx BioPharma IPO?

AzurRx BioPharma (AZRX) raised $15 million in an initial public offering (IPO) on Friday, September 9th 2016. The company issued 2,100,000 shares at $6.00-$8.00 per share. WallachBeth Capital and Network 1 Financial Securities acted as the underwriters for the IPO.

What other stocks do shareholders of AzurRx BioPharma own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AzurRx BioPharma investors own include SCYNEXIS (SCYX), Acasti Pharma (ACST), Sorrento Therapeutics (SRNE), Tonix Pharmaceuticals (TNXP), Vaxart (VXRT), Inovio Pharmaceuticals (INO) and Novavax (NVAX).

Company Calendar

• Today: 5/28/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:AZRX
• CIK: 1604191
• Web: www.azurrx.com
• Phone: (649) 699-7855
• Fax: N/A
• Employees: 12
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($11.50)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$32.67 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -482.96%
• Return on Assets: -258.47%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.33
• Quick Ratio: 1.33

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.76) per share
• Price / Book: -0.52

Miscellaneous

• Outstanding Shares: 9,326,000
• Free Float: 8,645,000
• Market Cap: $3.68 million
• Optionable: Not Optionable
• Beta: 1.51